Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib

Purpose: This study implements a physiologically based pharmacokinetic (PBPK) modelling approach to predict the effect of hydrastine and berberine, two major alkaloids present in goldenseal extract, on pharmacokinetics of imatinib and bosutinib. Methods: PBPK models of hydrastine and berberine were...

Full description

Saved in:
Bibliographic Details
Main Authors: Adiwidjaja, Jeffry, Boddy, Alan V., McLachlan, Andrew J.
Format: Article PeerReviewed
Language:English
Published: Springer Science and Business Media Deutschland GmbH 2022
Subjects:
Online Access:https://repository.ugm.ac.id/283068/1/Physiologically%20based%20pharmacokinetic%20model%20predictions%20of%20natural%20product-drug%20interactions%20between%20goldenseal%2C%20berberine%2C%20imatinib%20and%20bosutinib.pdf
https://repository.ugm.ac.id/283068/
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123083703&doi=10.1007%2fs00228-021-03266-y&partnerID=40&md5=80ba99ea75d46cb5070d02a79635dcec
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universitas Gadjah Mada
Language: English
id id-ugm-repo.283068
record_format dspace
spelling id-ugm-repo.2830682023-11-17T07:43:29Z https://repository.ugm.ac.id/283068/ Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib Adiwidjaja, Jeffry Boddy, Alan V. McLachlan, Andrew J. Pharmaceutical Sciences Purpose: This study implements a physiologically based pharmacokinetic (PBPK) modelling approach to predict the effect of hydrastine and berberine, two major alkaloids present in goldenseal extract, on pharmacokinetics of imatinib and bosutinib. Methods: PBPK models of hydrastine and berberine were developed in the Simcyp Simulator (version 17), integrating prior in vitro knowledge and published clinical pharmacokinetic data. The models account for reversible and irreversible (mechanism-based) inhibition of CYP3A enzymes as well as inhibition of the P-glycoprotein transporter. Inhibitory potencies of hydrastine and berberine on imatinib and bosutinib were estimated based on in vitro inhibition of metabolite formation. Results: The PBPK models provided reliable estimates on the magnitude of interactions due to co-administration of goldenseal extract or high-dose berberine on substrates of CYP3A enzymes (midazolam, indinavir and cyclosporine) and P-glycoprotein (digoxin). PBPK simulations predicted a moderate twofold increase (5th to 95th percentiles of prediction of 1.4–3.1) in systemic exposure (AUC) of bosutinib when co-administered with clinically relevant doses of goldenseal extract. A high dose of berberine (300 mg thrice daily) was also expected to affect bosutinib exposure, albeit to a lesser extent than that predicted with goldenseal (AUC ratio of 1.3, 5th to 95th percentile: 1.1–1.6). Conversely, the corresponding effects on imatinib exposure are unlikely to be of clinical importance (predicted AUC ratios of 1.0–1.2). Conclusion: PBPK model-based predictions highlighted potential clinically significant interactions between goldenseal extract and bosutinib, but not imatinib. Dose adjustment may need to be considered if co-administration is desirable. These findings should be confirmed with optimally designed controlled drug interaction studies. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. Springer Science and Business Media Deutschland GmbH 2022 Article PeerReviewed application/pdf en https://repository.ugm.ac.id/283068/1/Physiologically%20based%20pharmacokinetic%20model%20predictions%20of%20natural%20product-drug%20interactions%20between%20goldenseal%2C%20berberine%2C%20imatinib%20and%20bosutinib.pdf Adiwidjaja, Jeffry and Boddy, Alan V. and McLachlan, Andrew J. (2022) Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. European Journal of Clinical Pharmacology, 78 (4). 597 -611. ISSN 00316970 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123083703&doi=10.1007%2fs00228-021-03266-y&partnerID=40&md5=80ba99ea75d46cb5070d02a79635dcec
institution Universitas Gadjah Mada
building UGM Library
continent Asia
country Indonesia
Indonesia
content_provider UGM Library
collection Repository Civitas UGM
language English
topic Pharmaceutical Sciences
spellingShingle Pharmaceutical Sciences
Adiwidjaja, Jeffry
Boddy, Alan V.
McLachlan, Andrew J.
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
description Purpose: This study implements a physiologically based pharmacokinetic (PBPK) modelling approach to predict the effect of hydrastine and berberine, two major alkaloids present in goldenseal extract, on pharmacokinetics of imatinib and bosutinib. Methods: PBPK models of hydrastine and berberine were developed in the Simcyp Simulator (version 17), integrating prior in vitro knowledge and published clinical pharmacokinetic data. The models account for reversible and irreversible (mechanism-based) inhibition of CYP3A enzymes as well as inhibition of the P-glycoprotein transporter. Inhibitory potencies of hydrastine and berberine on imatinib and bosutinib were estimated based on in vitro inhibition of metabolite formation. Results: The PBPK models provided reliable estimates on the magnitude of interactions due to co-administration of goldenseal extract or high-dose berberine on substrates of CYP3A enzymes (midazolam, indinavir and cyclosporine) and P-glycoprotein (digoxin). PBPK simulations predicted a moderate twofold increase (5th to 95th percentiles of prediction of 1.4–3.1) in systemic exposure (AUC) of bosutinib when co-administered with clinically relevant doses of goldenseal extract. A high dose of berberine (300 mg thrice daily) was also expected to affect bosutinib exposure, albeit to a lesser extent than that predicted with goldenseal (AUC ratio of 1.3, 5th to 95th percentile: 1.1–1.6). Conversely, the corresponding effects on imatinib exposure are unlikely to be of clinical importance (predicted AUC ratios of 1.0–1.2). Conclusion: PBPK model-based predictions highlighted potential clinically significant interactions between goldenseal extract and bosutinib, but not imatinib. Dose adjustment may need to be considered if co-administration is desirable. These findings should be confirmed with optimally designed controlled drug interaction studies. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
format Article
PeerReviewed
author Adiwidjaja, Jeffry
Boddy, Alan V.
McLachlan, Andrew J.
author_facet Adiwidjaja, Jeffry
Boddy, Alan V.
McLachlan, Andrew J.
author_sort Adiwidjaja, Jeffry
title Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
title_short Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
title_full Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
title_fullStr Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
title_full_unstemmed Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
title_sort physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
publisher Springer Science and Business Media Deutschland GmbH
publishDate 2022
url https://repository.ugm.ac.id/283068/1/Physiologically%20based%20pharmacokinetic%20model%20predictions%20of%20natural%20product-drug%20interactions%20between%20goldenseal%2C%20berberine%2C%20imatinib%20and%20bosutinib.pdf
https://repository.ugm.ac.id/283068/
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123083703&doi=10.1007%2fs00228-021-03266-y&partnerID=40&md5=80ba99ea75d46cb5070d02a79635dcec
_version_ 1783956367820718080